MDGL Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), announced today its management team will participate in fireside chats at three upcoming investor conferences:

UBS Biopharma Conference 20235:00 pm ET on Wednesday, November 8, 2023.

6th Annual Evercore ISI HealthCONx Conference3:00 pm ET on Wednesday, Nov 29, 2023.

Piper Sandler 35th Annual Healthcare Conference1:00 pm ET on Thursday, November 30, 2023.

The fireside chats will be webcast and archived recordings will be available for replay in the Investors section of the Madrigal website after the events.

About Madrigal PharmaceuticalsMadrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s lead candidate, resmetirom, is a liver-directed oral therapy that is designed to target key underlying causes of NASH. For more information, visit www.madrigalpharma.com.

Investor Contact Alex Howarth, Madrigal Pharmaceuticals, Inc., IR@madrigalpharma.com

Media ContactChristopher Frates, Madrigal Pharmaceuticals, Inc., media@madrigalpharma.com